Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer.
Hu J, Yu A, Othmane B, Qiu D, Li H, Li C, Liu P, Ren W, Chen M, Gong G, Guo X, Zhang H, Chen J, Zu X. · 2021
Read Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer. by Hu J, Yu A, Othmane B, Qiu D, Li H, Li C, Liu P, Ren W, Chen M, Gong G, Guo X, Zhang H, Chen J, Zu X. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7847675.txt.
Introduction
Hu and co-authors study the protein Siglec15 in bladder cancer and the wider cancer field. Siglec15 is a rising target for a new style of immunotherapy. Its role in bladder cancer was unclear. The team mined RNA data from The Cancer Genome Atlas.
Siglec15 was overproduced in tumor settings across many cancers. In bladder cancer, high levels matched a quiet immune scene. Immune cells, checkpoints, and attack signals all ran low. Such tumors answered immunotherapy poorly. They did differ in subtype and drug response in other ways. The team built an immune risk score from these patterns. The score predicted survival and therapy response in test cohorts.
Catalog record
| CREATOR | Hu J, Yu A, Othmane B, Qiu D, Li H, Li C, Liu P, Ren W, Chen M, Gong G, Guo X, Zhang H, Chen J, Zu X. |
|---|---|
| YEAR | 2021 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 74 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer By Jiao Hu, Anze Yu, Belaydi Othmane, Dongxu Qiu, Huihuang Li, Chao Li, Peihua Liu, Wenbiao Ren, Minfeng Chen, Guanghui Gong, Xi Guo, Huihui Zhang Published in: Theranostics DOI: 10.7150/thno.53649 ABSTRACT Abstract Rationale: Siglec15 is an emerging target for normalization cancer immunotherapy. However, pan-cancer anti-Siglec15 treatment is not yet validated and the potential role of Siglec15 in bladder cancer (BLCA) remains elusive. Methods: We comprehensively evaluated the expression pattern and immunological role of Siglec15 using pan-cancer analysis based on RNA sequencing data obtained from The Cancer Genome Atlas. We then systematically correlated Siglec15 with immunological characteristics in the BLCA tumor microenvironment (TME), including immunomodulators, cancer immunity cycles, tumor-infiltrating immune cells (TIICs), immune checkpoints, and T cell inflamed score. We also analyzed the role of Siglec15 in predicting the molecular subtype and the response to several treatment options in BLCA. Our results were validated in several public cohorts as well as our BLCA tumor microarray cohort, the Xiangya cohort. We developed an immune risk score (IRS), validated it, and tested its ability to predict the prognosis and response to cancer immunotherapy. Results: We found that Siglec15 was specifically overexpressed in the TME of various cancers. We hypothesize that Siglec15 designs a non-inflamed TME in BLCA based on the evidence that Siglec15 negatively correlated with immunomodulators, TIICs, cancer immunity cycles, immune checkpoints, and T cell inflamed score. Bladder cancer with high Siglec15 expression was not sensitive to cancer immunotherapy, but exhibited a higher incidence of hyperprogression. High Siglec15 levels indicated a luminal subtype of BLCA characterized by lower immune infiltration, lower response to cancer immunotherapy and neoadjuvant chemotherapy, but higher response to anti-angiogenic therapy and targeted therapies such as blocking Siglec15, β-catenin, PPAR-γ, and FGFR3 pathways. Notably, a combination of anti-Siglec15 and cancer immunotherapy may be a more effective strategy than monotherapy. IRS can accurately predict the prognosis and response to cancer immunotherapy. Conclusions: Anti-Siglec15 immunotherapy might be suitable for BLCA treatment as Siglec15 correlates with a non-inflamed TME in BLCA. Siglec15 could also predict the molecular subtype and the response to several treatment options. Keywords: Siglec15, Bladder cancer, Immunotherapy, Molecular subtype, Tumor microenvironment INTRODUCTION Bladder cancer (BLCA) is the second most common urinary cancer 1. Despite neoadjuvant and adjuvant chemotherapy, the outcome for metastatic BLCA is poor 2. Cancer immunotherapy, including immune checkpoint blockade (ICB), has achieved promising survival benefits for advanced BLCA 3, 4. Although BLCA is an immunogenic cancer characterized by high tumor mutation burden (TMB) and neoantigens 5, only a small number of patients respond to ICB because of primary or secondary mechanisms of resistance to it 3, 4. An inflamed tumor microenvironment (TME) in conjunction with pre-existing anticancer immunity is necessary, but not sufficient, for the success of ICB 6-9. ICB inhibits tumor growth by re-invigorating tumor-cytotoxic T cells in TME, but does not induce their formation 10. Theoretically, molecules or pathways resulting in a non-inflamed TME will cause resistance to ICB. In BLCA, such molecules and pathways, including β-catenin, PPAR-γ, and FGFR3 pathways, have been shown to promote the formation of a non-inflamed TME by excluding the infiltration level of tumor-infiltrating immune cells (TIICs) 11-15. For patients with a non-inflamed TME, transforming it into an inflamed TME by reversing these ICB-resistant mechanisms is one of the top priorities along with promoting the recruitment of TIICs to drive tumor regression 16. Given the substantial economic burden and toxic side effects of cancer treatments, more robust and economic biomarkers that predict the response to ICB must be explored. PD-L1 is related to the clinical response of ICB in many clinical trials, but its predictive value may be weakened by many factors 17, 18. TMB, microsatellite instability (MSI), and the molecular subtype can predict the clinical response of BLCA to ICB. However, these biomarkers are detected using complex molecular methods, which are slow and expensive 3, 4. Moreover, molecular subtypes can predict the prognosis and some therapeutic responses of BLCA 19, but their widespread clinical application has failed so far. Therefore, there is an urgent medical need for the development of faster and economical molecular subtype predictors. Siglec15, a member of the sialic acid-binding immunoglobulin-like lectins family, is an emerging broad-spectrum target for normalization cancer immunotherapy, and is complementary to PD-L1 20, 21. Wang et al. demonstrated that Siglec15 promoted tumor growth by inhibiting the proliferation of CD8+ T cells, and Siglec15 inhibitors could relieve this immunosuppression 20. The results of a phase I clinical trial in advanced non-small cell lung cancer (NSCLC) indicated that Siglec15 inhibitors achieved a promising clinical response (NCT03665285). Currently, a phase II clinical trial is ongoing to assess this treatment's efficacy in solid tumors including NSCLC, ovarian cancer (OV), melanoma, breast cancer (BRCA), and colorectal cancer. However, it is critical to note that the potential of Siglec15 as a broad-spectrum therapeutic target was not validated in pan-cancers before initiating this phase II clinical trial. The recent progress of this phase II clinical trial in NSCLC and ovarian cancer has been slow, casting doubt on the validity of Siglec15 inhibitors in unselected cancer types (http://ir.nextcure.com/news-releases/news-release-details/nextcure-provides-interim-update-phase-2-portion-nc318). Recently, Li et al. performed a pan-cancer analysis on Siglec15 and confirmed that Siglec15 plays an immunoregulatory role in lung adenocarcinoma and may be a vital prognostic biomarker 22. However, the role of Siglec15 in BLCA should be further investigated. In this study, we performed a pan-cancer analysis of the expression patterns and immunological role of Siglec15. We found that BLCA may be a suitable candidate for anti-Siglec15 therapy. We also report that Siglec15 promotes the development of a non-inflamed TME in BLCA, and has the potential to predict the molecular subtype of BLCA. METHODS Figure 1 shows the workflow of this study. [Figure: Overview of the study design. (A) Data sources used in this study; (B) Correlations between Siglec15 and pan-cancer immunological elements. TIICs were estimated using ssGSEA algorithm. (C) Correlation between Siglec15 and the immunological status of the tumor microenvironment in BLCA. The immunological status includes immunomodulators, steps of the cancer-immunity cycle, immune checkpoints, T cell-inflamed score, and TIICs. (D) Role of Siglec15 in predicting the molecular subtypes in BLCA. (E) Role of Siglec15 in predicting therapeutic responses to immunotherapy, neoadjuvant/adjuvant chemotherapy, targeted therapy, EGFR therapy, and radiotherapy in BLCA. (F) Development of an immune risk score; (G) Sankey plot displaying the main results in this study. TIICs: tumor-infiltrating immune cells, IF: immunofluorescence.] Data retrieval and preprocessing The Cancer Genome Atlas (TCGA) data: The pan-cancer RNA sequencing (RNA-seq) data (FPKM value), somatic mutation data, and survival information were downloaded from the UCSC Xena data portal 23. Data on RNA-seq were log2 transformed, while somatic mutation data were analyzed using VarScan2 and then used to calculate TMB. MSI data were collected from the supplementary files of Bonneville's study 24. The copy number variation (CNV) data, processed using the GISTIC algorithm, were downloaded from the UCSC Xena data portal, whereas the methylation data were downloaded from the LinkedOmics data portal 25. The abbreviations for various cancer types are given in Table S1. Gene Expression Omnibus (GEO): Eight BLCA GEO cohorts with detailed survival data were downloaded, namely GSE13507, GSE31684, GSE48075, GSE48277, GSE69795, GSE70691, GSE32894, and GSE5287.